| Literature DB >> 31687255 |
Kanokporn Chukua1, Chayanont Netsawang1, Kittipoom Padungthai1, Thanitchet Khetkham2, Piyaporn Chokevittaya3, Onapinya Poonjearansilp3, Sariya Prachuktum3, Sudatip Kositamongkol3, Wiliporn Techasatit3, Phakatip Silapamongkolkul3, Wallee Satayasai3, Tasama Pusongchai3, Pacharapan Surapolchai3, Kitiwan Rojnueangnit3.
Abstract
Children with Down syndrome (DS) are 150 times more likely to develop acute myeloid leukemia (ML-DS), compared with those without. One risk factor is transient abnormal myelopoiesis (TAM). Somatic truncating GATA1 mutations are found in most TAM patients and are markers for future ML-DS. We identified two novel frameshift mutations in our seven newborns with DS and TAM: a heterozygous mutation of 17 nucleotide duplication (c.154_170 dup) and a heterozygous 9-nucleotide deletion combined with a 2-nucleotide insertion (c.150_158delins CT). Both mutations introduced a truncated GATA1 protein. Thus, neonates with DS and TAM require frequent ML-DS monitoring. © Thieme Medical Publishers.Entities:
Keywords: Down syndrome; GATA1 mutation ; transient abnormal myelopoiesis
Year: 2019 PMID: 31687255 PMCID: PMC6824893 DOI: 10.1055/s-0039-1696971
Source DB: PubMed Journal: J Pediatr Genet ISSN: 2146-460X